Article
Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.
The Journal of clinical investigation - 2 Nov 2020
Prudencio Mercedes, Humphrey Jack, Pickles Sarah, Brown Anna-Leigh, Hill Sarah E, Kachergus Jennifer M, Shi J, Heckman Michael G, Spiegel Matthew R, Cook Casey, Song Yuping, Yue Mei, Daughrity Lillian M, Carlomagno Yari, Jansen-West Karen, de Castro Cristhoper Fernandez, DeTure Michael, Koga Shunsuke, Wang Ying-Chih, Sivakumar Prasanth, Bodo Cristian, Candalija Ana, Talbot Kevin, Selvaraj Bhuvaneish T, Burr Karen, Chandran Siddharthan, Newcombe Jia, Lashley Tammaryn, Hubbard Isabel, Catalano Demetra, Kim Duyang, Propp Nadia, Fennessey Samantha, Fagegaltier Delphine, Phatnani Hemali, Secrier Maria, Fisher Elizabeth Mc, Oskarsson Björn, van Blitterswijk Marka, Rademakers Rosa, Graff-Radford Neil R, Boeve Bradley F, Knopman David S, Petersen Ronald C, Josephs Keith A, Thompson E Aubrey, Raj Towfique, Ward Michael, Dickson Dennis W, Gendron Tania F, Fratta Pietro, Petrucelli Leonard
Abstract excerpt
No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish between patients with FTLD-TDP and FTLD-tau. Therefore, we...
Read the complete abstract on PubMed